Breaking News Erdosteine to be tested as part of COVID-19 treatment
Recipharm is pleased to announce that Erdosteine will be tested in a clinical study as an add-on treatment for COVID-19 patients.
The clinical study, which began on 7th April, is being conducted in clinical centres actively involved in COVID-19 treatment in Milan and Bergamo. Both Milan and Bergamo are based in Lombardy, the Italian region most affected by the virus.
The study, which involves around 100 patients affected by COVID-19 and discharged from hospitals, is evaluating if Erdosteine improves respiratory symptoms (dyspnea, cough, asthenia) and reduces the time to reach a negative test result for SARS-CoV-2. First results from the study are expected in two months.
The hypothesis is that the multiple mechanisms of action of Erdosteine (antioxidant, mucoactive, anti-inflammatory and antibiotic enhancer) may improve respiratory function and could thus potentially benefit patients affected by COVID-19.
Erdosteine was discovered and developed in Italy at Recipharm’s facility in Paderno Dugnano and is in Italy and several other countries indicated for the treatment of acute and chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD).
Dr. Katherine Salessi Nia, Medical Manager, for Erdosteine commented: ”There is already some rationale that mucolytic drugs could be part of the treatment of COVID-19 patients. Considering the specific properties of our molecule and the proven clinical results in COPD treatment, we truly hope that Erdosteine could play a role in the treatment of this pandemic pathology”.
Erdosteine is Edmond Pharma's most successful Molecule, produced both in API and finished product forms, totally developed in house with Edmond research. Today it is marketed in nearly 40 countries worldwide.
Erdosteine is a mucolitic and it has a clinical efficacy in acute respiratory disease and in COPD with an unique mechanism of action.
The Erdosteine molecule is characterised by the presence of two sulphur atoms: one in the aliphatic side chain and the second enclosed in the heterocyclic ring (thiolactone). With these two blocked thiol groups, Erdosteine is an inactive pro-drug. Following first-pass metabolism, the opening of the thiolactone ring and desacetylation of the aliphatic side chain liberates free SH groups, with the formation of the active metabolite I, N-thiodiglycolylhomocysteine (Metabolite I), so, Erdosteine has no direct effect on gastric mucus.
Co-administration of antibiotics do not interfere to the action of the drug, unlike other compounds with similar therapeutic indications. Clinical findings also demonstrate that Erdosteine has good gastric tolerability after oral administration, and do not cause reflux phenomena like others thiols.
Compounds containing thiol groups often have an unpleasant smell and after intake may frequently cause reflux phenomena. These problems do not occur with Erdosteine.
The unique chemical structure of Erdosteine results in a compound that has multiple properties that are relevant to the treatment of chronic bronchitis, namely:
- muco-modulatory activity
- antibacterial adhesivity – infection prevention
- anti-inflammatory activity
- antioxidant activity
- potentiation (in vivo) of antibiotic therapy in respiratory infections
the present that anticipates the future
Modern life history had two big economical accelerators who boosted the quality and the quantity of life: coal and oil. Indeed, the growth of the industrial civilization is mentioned as “coal age” and the contemporary age as the “oil age".
Both these “ages” had as side effect to significantly increase environmental and specially the air pollution. It’s in the coal age that the word “smog” has been coined, and nowadays the quality of air is measured with the quality and the quantity of the micro-particles (PM10 etc). All the major agencies of the ambience (as other agencies in the world) gives maps of density of pollutants.
Man does not adapt himself to the change in the quality of the air and this is has led to of a lot of pathologies, not only of the respiratory tract. Scientific and politic world meet to confirm the impact of this “cost of the civilization”, and they send out serveral guidelines. These rules are made both to prevent the rise of respiratory diseases and to suggest several treatment.
As the epidemiologial importance of these disease (COPD will be the third cause of death in the world in 2030), research of new drugs or of a better use of known active principles, (back to the future) is one of the most important frontiers of pharmacological R&D. Edmond Pharma, heavily involved in respiratory R&D, opens this site in order to promote (accordingly to the laws about the communication to the patients) the diffusion of knowledge on these items with a focus on the updates.